BridgeMD
New treatment option for Ovarian Cancer
Official title PARP (Poly (ADP-ribose) Polymerase) Inhibitor With or Without Angiogenesis Inhibitor in Homologous Recombination Deficient Primary Ovarian Cancer, Fallopian-Tube Cancer, or Primary Peritoneal Cancer
ClinicalTrials.gov ID: NCT07472140
What this study is testing
What is PARP inhibitor + Bevacizumab?
PARP inhibitor + Bevacizumab is an investigational medicine, given as an infusion into a vein, being studied as a potential treatment for ovarian cancer.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This is a randomized trial evaluating the results of using of PARP inhibitor combined with angiogenesis inhibitor. in patients with homologous recombination deficient primary ovarian cancer, fallopian-tube cancer, or primary peritoneal cancer of the III-IV stages.
- Phase 3: a large, late-stage study
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 75, women only
You may be able to join if
- Age ≥18-≤75 years.
- Histologically confirmed diagnosis of serous or endometrioid high-grade ovarian cancer, fallopian-tube cancer or primary peritoneal cancer.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- Possibility of performing diagnostic laparoscopy or cytoreductive surgery.
- Presence of homologous recombination deficiency (HRD).
You likely can't join if
- Presence of another active malignant invasive neoplasm.
- Pregnancy or lactation period.
- Disease progression during treatment.
See the full eligibility criteria
- Age ≥18-≤75 years.
- Histologically confirmed diagnosis of serous or endometrioid high-grade ovarian cancer, fallopian-tube cancer or primary peritoneal cancer.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- Possibility of performing diagnostic laparoscopy or cytoreductive surgery.
- Presence of homologous recombination deficiency (HRD).
- No contraindications to chemotherapy, or bevacizumab.
- Signed informed consent to participate in the study.
- Presence of another active malignant invasive neoplasm.
- Pregnancy or lactation period.
- Disease progression during treatment.
The study team makes the final eligibility decision.
Where it's taking place
- Minsk, Lesnoy, Belarus
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling female, 18 years to 75 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Minsk, Lesnoy, Belarus. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.